Next generation of SERMs being seen in clinic.
Smigel
K
K
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D017326:Clinical Trials, Phase III as Topic; D004965:Estrogen Antagonists / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control*; D010880:Piperidines / Q000494:pharmacology*; D020849:Raloxifene Hydrochloride; D011960:Receptors, Estrogen / Q000187:drug effects*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D010880:Piperidines; D011960:Receptors, Estrogen; D020849:Raloxifene Hydrochloride